BRIEF-Regeneron Expands Clinical-Stage Obesity Portfolio

Reuters
02 Jun
BRIEF-Regeneron Expands Clinical-Stage Obesity Portfolio

June 2 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:

  • REGENERON EXPANDS CLINICAL-STAGE OBESITY PORTFOLIO WITH STRATEGIC IN-LICENSING OF NOVEL DUAL GLP-1/GIP RECEPTOR AGONIST

  • REGENERON PHARMACEUTICALS INC - TO PAY $80 MILLION UPFRONT TO HANSOH

  • REGENERON PHARMACEUTICALS INC: POTENTIAL ADDITIONAL PAYMENTS OF UP TO $1.93 BILLION UNDER DEAL

Source text: ID:nGNXy8WRz

Further company coverage: REGN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10